Compare J M Smucker Co (SJM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J M Smucker Co vs TG Therapeutics Inc — how do they compare? J M Smucker Co trades at $123.58 (market cap $13.32B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: J M Smucker Co is the larger of the two by market cap, and J M Smucker Co pays a 3.59% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SJM | TGTX | |
|---|---|---|
Market Cap | $13.32B | $8.53B |
Sector | Consumer Staples | Health |
52-Week High | $132.34 | $59.06 |
52-Week Low | $89.53 | $26.94 |
Enterprise Value | $20.17B | $8.74B |
Dividend Yield | 3.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SJM trades at $124.66, down 1.13% on the day, with a bullish technical signal per moving averages despite oscillators showing bearish momentum. The company reported strong Q1 2027 earnings, beating estimates with EPS of $3.24, and raised full-year guidance. Valuation metrics include a P/E of 58.25 and P/S of 1.45, while recent news highlights CEO and CFO stock sales and positive analyst sentiment.
Outlook is positive with a consensus price target of $144.78, implying 16% upside, supported by earnings momentum and dividend yield. Risks include high debt levels, with debt-to-asset ratio at 43.71% in 2025, and volatile net income margins, which turned negative in 2025. Investors should weigh strong recent performance against financial leverage and insider selling activity.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
